Treatment of al amyloidosis with melphalan, prednisone, and colchicine

Authors

  • Merrill D. Benson MD

    Chief, Corresponding author
    1. Department of Medicine, Rheumatology Division, Indiana University School of Medicine and the Rheumatology Section, Richard L. Roudebush Veterans Administration Medical Center, Indianapolis, Indiana
    • Rheumatology Section, Richard L. Roudebush Veterans Administration Medical Center, 1481 West 10th Street, Indianapolis, IN 46202
    Search for more papers by this author

Abstract

Seven patients with immunoglobulin type (AL) amyloidosis were treated with combination chemotherapy, including melphalan, prednisone, and colchicine. Two patients died within 5 months of the beginning of therapy. Both had amyloid cardiomyopathy. Five patients were alive 17–60 months after the start of therapy, and none had shown progression of disease. The most significant findings were the resolution of the nephrotic syndrome in 2 patients, and improvement of liver function, as demonstrated by excretion of indocyanine green, in 2 patients. These results are encouraging and support the need for further studies of this regimen of combination chemotherapy for patients with AL amyloidosis.

Ancillary